<h1 id="thyroid-storm-treatment-strategies">Thyroid Storm: Treatment Strategies</h1>
<p><strong>Take Home Points</strong></p>
<ul>
<li>Endocrinologic emergencies are too easily labeled as “sepsis”, as they can present very similarly. </li>
<li>A <a href="http://www.medicalcriteria.com/site/index.php?option=com_content&amp;view=article&amp;id=262%3Aendts&amp;catid=52%3Aendocrinology-and-metabolism&amp;Itemid=80&amp;lang=en">scoring system</a> developed by Burch and Wartofsky can assist in determining the likelihood of thyroid storm in patients based on presenting signs and symptoms. </li>
<li>A previous <a href="http://academiclifeinem.com/diagnosing-hyperthyroidism/">ALiEM blog post</a> further discusses some of the nuances associated with the diagnosis of thyroid storm.</li>
</ul>
<p><strong>You can think of the mainstay treatment strategies of thyroid storm based on three main goals:</strong></p>
<ol>
<li>Block the production and release of thyroid hormone </li>
<li>Block the sympathetic outflow </li>
<li>Block peripheral conversion of T4 to T3 </li>
</ol>
<p><strong>Click <a href="http://academiclifeinem.com/thyroid-storm-treatment-strategies/">here</a> for full ALiEM blog post</strong></p>
<h2 id="thionamides">THIONAMIDES</h2>
<ul>
<li>Mechanism of action: Inhibit thyroid peroxidase, an enzyme involved in the production of T3 and T4 through the iodination of tyrosine residues on thyroglobulin</li>
<li>Agents: <span class="drug">propylthiouriacil</span> (PTU) and <span class="drug">methimazole</span> (MMI)</li>
<li>Dosing<ul>
<li><strong>PTU</strong><ul>
<li>Loading dose: 600 to 1000 mg PO</li>
<li>Maintenance dose: 200 to 250 mg PO q4h</li>
</ul>
</li>
<li><strong>MMI</strong><ul>
<li>Loading dose: 20 to 25 mg</li>
<li>Maintenance dose: 20 to 25 mg PO q4h</li>
</ul>
</li>
</ul>
</li>
</ul>
<!-- -->
<ul>
<li>No head-to-head trials have shown any benefit of using one thionamide over another in the management of thyroid storm</li>
<li>Additional benefit of <span class="drug">PTU</span> in thyroid storm:<ul>
<li>Inhibition of the peripheral conversion of T4 to T3 (3rd “B”)</li>
</ul>
</li>
<li>Alternative routes of administration:<ul>
<li><span class="drug">PTU</span> and <span class="drug">MMI</span> can both be administered through the rectal route as a suppository and retention enema<ul>
<li>Shown to have good response in several trials [<a href="http://www.ncbi.nlm.nih.gov/pubmed/3410604">Bartle (1988)</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=21254909">Alfadhi (2011)</a>]</li>
</ul>
</li>
<li>Intravenous (IV) thionamides are currently not commercially available in the United States<ul>
<li>IV formulation of MMI is available in Europe</li>
<li>Success reported in case reports and case series of treating thyroid storm with IV MMI compounded formulations [<a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=3224594">Sowinski (1988)</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed/16889494">Hodak (2006)</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed/8435884">Solomon (1993)</a>]</li>
</ul>
</li>
</ul>
</li>
<li>Pregnancy considerations:<ul>
<li><span class="drug">PTU</span> is generally preferred over <span class="drug">MMI</span></li>
</ul>
</li>
<li>Adverse effects:<ul>
<li><span class="drug">PTU</span>: black box warning for severe and/or life-threatening hepatotoxicity issued by FDA in 2010</li>
<li>Agranulocytosis:<ul>
<li>Can occur at any point during treatment</li>
<li>Tends to be dose-related with MMI, unlike PTU</li>
<li>Granulocyte colony-stimulating factors (G-CSFs) can be used in the management of thionamide-induced agranulocytosis</li>
</ul>
</li>
</ul>
</li>
</ul>
<h2 id="inorganic-iodine">INORGANIC IODINE</h2>
<ul>
<li>Used to prevent the release of pre-formed thyroid hormone from the thyroid gland</li>
<li>Various formulations:<ul>
<li><strong>Saturated solution of potassium iodide (SSKI)</strong>: 5 drops PO, NG, or PR q6h</li>
<li><strong>Lugol’s solution:</strong> 8 drops PO, NG, or PR q6h</li>
<li><strong>Sodium iodide:</strong> 500 mg IV q12h </li>
</ul>
</li>
<li>Administration of inorganic iodine should be delayed for at least one hour after initiation of thionamide therapy</li>
<li><span class="drug">Iodine</span> load can serve as a substrate for thyroid hormone synthesis and exacerbate thyroid storm</li>
<li><span class="drug">Iodine</span> content of formations (NOTE: Solutions <strong>are not interchangeable</strong>.)</li>
</ul>
<table>
<thead>
<tr>
<th>Iodine Solution</th>
<th>Content of Iodine Per Drop</th>
</tr>
</thead>
<tbody>
<tr>
<td>SSKI</td>
<td>38 mg iodine</td>
</tr>
<tr>
<td>Lugol&#39;s Solution</td>
<td>8 mg iodine</td>
</tr>
</tbody>
</table>
<ul>
<li>The dose is by the <strong>dropperful</strong> (as opposed to mL) of solution</li>
<li>Dissolve the dose in solution of 3 to 4 ounces of milk, fruit juice, or water to ensure that the full dose is given and to mask the bitter taste</li>
<li>If true allergy to iodine or contraindication to iodine therapy (e.g. <span class="drug">amiodarone</span>-induced thyrotoxicosis):<ul>
<li>Consider administration of <span class="drug">lithium</span> carbonate 300 mg PO or NG q6h</li>
<li>Maintain <span class="drug">lithium</span> level within range of 0.8 to 1.2 mEq/L</li>
</ul>
</li>
</ul>
<h2 id="beta-blockade">BETA BLOCKADE</h2>
<ul>
<li>Enhanced α- and β-adrenergic stimulation in the setting of thyroid storm leads to clinical manifestations</li>
<li><p><strong><span class="drug">Propranolol</span>:</strong> most commonly used agent</p>
<ul>
<li>Inhibits peripheral conversion of T4 to T3 (3nd “B”)<ul>
<li>Effect not demonstrated considerably with other β-antagonists</li>
</ul>
</li>
<li>Blocks non-selective β-adrenergic receptors to allow for effective treatment of systemic effects, such as tremor, tachycardia, agitation, fever, diaphoresis, psychosis (2nd “B”)</li>
<li>Dose: 60 to 80 mg PO q4h<ul>
<li>Proper dosing of <span class="drug">propranolol</span> is essential because of dose-dependent effects on inhibition of peripheral conversion of thyroid hormone (&gt; 160 mg/day), and rapid metabolism of the agent in the setting of thyroid storm</li>
</ul>
</li>
<li>Alternative route of <span class="drug">propranolol</span>: IV formulation (determine availability at your institution)</li>
<li><p>Two-step method for administration:</p>
</li>
<li><p>Test dose: 0.5 to 1 mg as slow IV push administered over 10 minutes</p>
</li>
<li>Subsequent doses: 1 to 3 mg IV over 10 to 15 minutes every few hours to desired effect with monitoring of cardiac rhythm</li>
</ul>
</li>
<li><strong><span class="drug">Esmolol</span></strong> can be considered as an alternative agent</li>
<li>Contraindications to beta blockade: guanethidine or reserpine with close monitoring for hypotension</li>
</ul>
<h2 id="corticosteroids">CORTICOSTEROIDS</h2>
<ul>
<li>Depression of the hypothalamic-pituitary axis commonly occurs in the setting of thyroid storm</li>
<li>Additional benefit: inhibition of peripheral conversion of T4 to T3 (3rd “B”)</li>
<li><strong><span class="drug">Hydrocortisone</span></strong>: loading dose of 300 mg IV followed by maintenance dose of 100 mg IV q8h (or dose equivalent)</li>
</ul>
<h2 id="other-therapies">OTHER THERAPIES</h2>
<ul>
<li><strong><span class="drug">Cholestyramine</span> resin:</strong><ul>
<li>Can be used to interrupt enterohepatic recirculation of thyroid hormone, leading to decreased circulating levels of thyroid hormone [<a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=7054215">Nabil (1982)</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed/8784067">Mercado (1996)</a>]</li>
<li>Dose: 4 g PO q6h</li>
</ul>
</li>
<li><strong>Supportive measures</strong><ul>
<li>Fluid resuscitation</li>
<li>Dissipation of heat with various cooling modalities for hyperthermia control</li>
<li>Benzodiazepines for control of agitation and to minimize sympathetic outflow</li>
</ul>
</li>
</ul>
<h2 id="references">References</h2>
<ul>
<li><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=3224594">Sowinski J, Junik R, Gembicki M. Effectiveness of intravenous administration of methimazole in patients with thyroid crisis. Endokrynol Pol 1988; 39:67-73.</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/pubmed/16889494">Hodak SP, Huang C, Clarke D, et al. Intravenous methimazole in the treatment of refractory hyperthyroidism. Thyroid 2006; 16:691-695.</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/pubmed/8435884">Solomon BL, Wartofsky L, Burman KD. Adjunctive cholestyramine therapy for thyrotoxicosis. Clin Endocrinol 1993;38:39-43.</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/pubmed/8784067">Mercado M, Mendoza-Zubieta V, Bautista-Osorio R, et al. Treatment of hyperthyroidism with a combination of methimazole and cholestyramine. J Clin Endocrinol Metab 1996; 81:3191-3193.</a></li>
<li><a href="Mercado%20M,%20Mendoza-Zubieta%20V,%20Bautista-Osorio%20R,%20et%20al.%20Treatment%20of%20hyperthyroidism%20with%20a%20combination%20of%20methimazole%20and%20cholestyramine.%20J%20Clin%20Endocrinol%20Metab%201996;%2081:3191-3193.%20">Burch HB, Wartofsky L. Life-threatening thyrotoxicosis. Thyroid storm. Endocrinol Metab Clin North Am 1993; 22:263-277.</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/pubmed/3410604">Bartle WR, Walker SE, Silverberg JD. Rectal absorption of propylthiouracil. Int J Clin Pharmacol Ther Toxicol 1988; 26:285-287.</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=21254909">Alfadhli E, Gianoukakis AG. Management of severe thyrotoxicosis when the gastrointestinal tract is compromised. Thyroid 2011; 21:215-220.</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=7054215">Nabil N, Miner DJ, Amatruda JM. Methimazole: an alternative route of administration. J Clin Endocrinol Metab 1982; 54:180-181.</a></li>
</ul>
